Drug Trial Radar · NCT05904028
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
603
Actual
Start
Nov 9, 2023
Primary completion
Jul 30, 2027
Study completion Jul 30, 2027
Sponsor
- Lead sponsor
- Jaeb Center for Health ResearchAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institutes of Health (NIH); National Eye Institute (NEI); Juvenile Diabetes Research Foundation
- First posted
- Jun 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.
Conditions
- Neovascular Age-related Macular Degeneration
Interventions
Intravitreal injections of 6 mg faricimab on a Treat and Extend scheduleDrug
Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule
Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment scheduleDevice
Intravitreal injections of 6 mg faricimab on a Home OCT-guided treatment schedule
Primary outcomes
What the sponsor says the trial is designed to measure.
- E-ETDRS Change in Visual Acuity Letter ScoreTime frame: Baseline to 104 weeks
- Number of intravitreal injections of Faricimab (6.0 mg) in the study eyeTime frame: Baseline to 104 weeks
Locations
64 sites in 2 countries. Site status is shown where the registry gives one.
Kent W. Small, MD, AMC
Glendale, California
Loma Linda University
Loma Linda, California
East Bay Retina Consultants, Inc.
Oakland, California
Kaiser Permanente - Oakland
Oakland, California
Southern California Desert Retina Consultants, Inc.
Palm Desert, California
UC Davis Health Eye Center
Sacramento, California
Macula Retina Vitreous Institute
Torrance, California
Bay Area Retina Associates A Medical Group
Walnut Creek, California
Retina Consultants
Manchester, Connecticut
National Ophthalmic Research Institute
Fort Myers, Florida
University of Florida- Jacksonville
Jacksonville, Florida
Florida Retina Institute, James A. Staman, MD, PA- Jacksonville
Jacksonville, Florida
Argus Research Center, Inc
Naples, Florida
Southeast Eye Institute, P.A. dba Eye Associates of Pinellas
Pinellas Park, Florida
Retina Associates of Sarasota
Sarasota, Florida
Sarasota Retina Institute
Sarasota, Florida
Retina Associates of Florida, LLC
Tampa, Florida
Southeast Retina Center, P.C.
Augusta, Georgia
Thomas Eye Group
Sandy Springs, Georgia
Northwestern Memorial Group
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
UIC - Dept of Ophthalmology & Visual Sciences
Chicago, Illinois
The Trustees of Indiana University
Indianapolis, Indiana
Midwest Eye Institute
Indianapolis, Indiana
Wolfe Clinic, P.C.- West Des Moines
West Des Moines, Iowa
Mid-America Retina Consultants, P.A.
Overland Park, Kansas
University of Kentucky Advanced Eye Care
Lexington, Kentucky
Elman Retina Group, BA
Baltimore, Maryland
Johns Hopkins University
Baltimore, Maryland
Valley Eye Physicians and Surgeons
Ayer, Massachusetts
Joslin Diabetes Center
Boston, Massachusetts
Henry Ford Health System
Detroit, Michigan
Retina Associates of Michigan
Grand Blanc, Michigan
Associated Retinal Consultants, P.C.
Royal Oak, Michigan
Associated Retinal Consultants
Traverse City, Michigan
The Retina Institute
St Louis, Missouri
Associated Retinal Surgeons d/b/a Mid Atlantic Retina
Cherry Hill, New Jersey
New York University Langone Health
New York, New York
Macula Care
New York, New York
Vitreous Retina Macula Consultants of NY - VRMNY
New York, New York
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.